PNC-27 P27
p53-derived peptide
Synthetic peptide joining a p53-derived segment to a membrane-penetrating leader, studied in cancer-cell research for HDM-2 binding and pores.
Evidence level. Evidence is mostly cell-based, cosmetic-ingredient data, or otherwise limited. About the badges
- Class
- p53-derived peptide
- Category
- Antioxidants & Specialty
- Type
- Single compound
- Abbreviation
- P27
- Development and regulatory status
- Not approved; preclinical research peptide
What researchers study
Synthetic anti-cancer research peptide combining a p53-derived segment with a membrane-penetrating leader. Reported to bind HDM-2 in cancer-cell membranes, forming transmembrane pores that cause necrosis, and to disrupt mitochondrial membranes.
Research areas
- Cancer-cell membrane pore formation
- HDM-2 binding studies
- Mitochondrial disruption in cancer cells
- Selectivity comparisons with non-cancer cells
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- cell culture
In MIA-PaCa-2 pancreatic cancer cells an antibody to the HDM-2 p53-binding site blocked PNC-27-induced necrosis, whereas control serum did not
- cell culture
PNC-27-treated cancer cells failed to retain mitochondrial dye while lysosomes retained theirs
